Washington, DC 20006-5349
HELPLINE
The Mesothelioma Applied Research Foundation is excited to announce its latest research grant recipients, awarding a total of $300,000. This brings the Foundation’s
At the Mesothelioma Applied Research Foundation, we are guided by the three core pillars that define our purpose: funding groundbreaking research, providing essential treatment support
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
